These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38763174)

  • 1. Twin Prime Editing Mediated Exon Skipping/Reinsertion for Restored Collagen VII Expression in Recessive Dystrophic Epidermolysis Bullosa.
    Steinbeck BJ; Gao XD; McElroy AN; Pandey S; Doman JL; Riddle MJ; Xia L; Chen W; Eide CR; Lengert AH; Han SW; Blazar BR; Wandall HH; Dabelsteen S; Liu DR; Tolar J; Osborn MJ
    J Invest Dermatol; 2024 May; ():. PubMed ID: 38763174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
    Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE
    Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.
    Turczynski S; Titeux M; Tonasso L; Décha A; Ishida-Yamamoto A; Hovnanian A
    J Invest Dermatol; 2016 Dec; 136(12):2387-2395. PubMed ID: 27498345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly efficient CRISPR/Cas9-mediated exon skipping for recessive dystrophic epidermolysis bullosa.
    du Rand A; Hunt J; Samson C; Loef E; Malhi C; Meidinger S; Chen CJ; Nutsford A; Taylor J; Dunbar R; Purvis D; Feisst V; Sheppard H
    Bioeng Transl Med; 2024 Jul; 9(4):e10640. PubMed ID: 39036091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of mutations of the type VII collagen gene (COL7A1) in recessive dystrophic epidermolysis bullosa mitis (M-RDEB) from three Korean patients.
    Ryoo YW; Kim BC; Lee KS
    J Dermatol Sci; 2001 Jun; 26(2):125-32. PubMed ID: 11378329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair.
    Izmiryan A; Ganier C; Bovolenta M; Schmitt A; Mavilio F; Hovnanian A
    Mol Ther Nucleic Acids; 2018 Sep; 12():554-567. PubMed ID: 30195791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa.
    Bremer J; Bornert O; Nyström A; Gostynski A; Jonkman MF; Aartsma-Rus A; van den Akker PC; Pasmooij AM
    Mol Ther Nucleic Acids; 2016 Oct; 5(10):e379. PubMed ID: 27754488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa.
    Wang X; Wang X; Li Y; A S; Qiu B; Bushmalyova A; He Z; Wang W; Lara-Sáez I
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101134. PubMed ID: 38027067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.
    Bonafont J; Mencía Á; García M; Torres R; Rodríguez S; Carretero M; Chacón-Solano E; Modamio-Høybjør S; Marinas L; León C; Escamez MJ; Hausser I; Del Río M; Murillas R; Larcher F
    Mol Ther; 2019 May; 27(5):986-998. PubMed ID: 30930113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs.
    Osborn MJ; Newby GA; McElroy AN; Knipping F; Nielsen SC; Riddle MJ; Xia L; Chen W; Eide CR; Webber BR; Wandall HH; Dabelsteen S; Blazar BR; Liu DR; Tolar J
    J Invest Dermatol; 2020 Feb; 140(2):338-347.e5. PubMed ID: 31437443
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Liemberger B; Bischof J; Ablinger M; Hainzl S; Murauer EM; Lackner N; Ebner P; Kocher T; Nyström A; Wally V; Mayr E; Guttmann-Gruber C; Hofbauer JP; Bauer JW; Koller U
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells.
    Mencía Á; Chamorro C; Bonafont J; Duarte B; Holguin A; Illera N; Llames SG; Escámez MJ; Hausser I; Del Río M; Larcher F; Murillas R
    Mol Ther Nucleic Acids; 2018 Jun; 11():68-78. PubMed ID: 29858091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa.
    Hainzl S; Trattner L; Liemberger B; Bischof J; Kocher T; Ablinger M; Nyström A; Obermayer A; Klausegger A; Guttmann-Gruber C; Wally V; Bauer JW; Hofbauer JP; Koller U
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two novel mutations on exon 8 and intron 65 of COL7A1 gene in two Chinese brothers result in recessive dystrophic epidermolysis bullosa.
    Lin Y; Chen XJ; Liu W; Gong B; Xie J; Xiong JH; Cheng J; Duan XL; Lin ZC; Huang LL; Wan HY; Liu XQ; Song LH; Yang ZL
    PLoS One; 2012; 7(11):e50579. PubMed ID: 23226319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation.
    Sheriff A; Guri I; Zebrowska P; Llopis-Hernandez V; Brooks IR; Tekkela S; Subramaniam K; Gebrezgabher R; Naso G; Petrova A; Balon K; Onoufriadis A; Kujawa D; Kotulska M; Newby G; Łaczmański Ł; Liu DR; McGrath JA; Jacków J
    Sci Rep; 2022 Nov; 12(1):19643. PubMed ID: 36385635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keratinocyte-/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation.
    Ito K; Sawamura D; Goto M; Nakamura H; Nishie W; Sakai K; Natsuga K; Shinkuma S; Shibaki A; Uitto J; Denton CP; Nakajima O; Akiyama M; Shimizu H
    Am J Pathol; 2009 Dec; 175(6):2508-17. PubMed ID: 19893033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations.
    McGrath JA; Ashton GH; Mellerio JE; Salas-Alanis JC; Swensson O; McMillan JR; Eady RA
    J Invest Dermatol; 1999 Sep; 113(3):314-21. PubMed ID: 10469327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five Novel
    Yan Y; Meng Z; Hao S; Wang F; Jin X; Sun D; Gao H; Ma X
    Ann Clin Lab Sci; 2018 Jan; 48(1):100-105. PubMed ID: 29531004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells.
    Jacków J; Guo Z; Hansen C; Abaci HE; Doucet YS; Shin JU; Hayashi R; DeLorenzo D; Kabata Y; Shinkuma S; Salas-Alanis JC; Christiano AM
    Proc Natl Acad Sci U S A; 2019 Dec; 116(52):26846-26852. PubMed ID: 31818947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Novel Biallelic Causative Variants in
    Fozia F; Nazli R; Alrashed MM; Ghneim HK; Haq ZU; Jabeen M; Alam Khan S; Ahmad I; Bourhia M; Aboul-Soud MAM
    Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.